An Observational Study on Patients With Non-Squamous NSCLC Who Reached A Long PFS After Avastin (Bevacizumab)-Based First-Line Therapy

Completed

• Conditions: Non-Squamous Non-Small Cell Lung Cancer

• Registration Number: NCT01343914
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This retrospective observational study will analyse demographic, clinical and treatment-related data of patients with non-squamous non-small cell lung cancer (NSCLC) who had reached \>/= 9 months of progression-free survival after Avastin (bevacizumab)-based first-line therapy. Data will be collected for approximately 9 months.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-04-12
• Study First Submitted QC: 2011-04-27
• Study First Posted: 2011-04-28
• Study Start: 2011-06
• Primary Completion: 2011-12
• Study Completion: 2011-12
• Status Verified: 2016-11
• Last Update Submitted: 2016-11-01
• Last Update Posted: 2016-11-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 118

Inclusion Criteria

• Adult patients, >/= 18 years of age
• Non-squamous non-small cell lung cancer (NSCLC) treated with first-line Avastin-based therapy
• Progression-free survival of >/= 9 months reached

Read More

Exclusion Criteria

• N/A

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression-free survival (>9 months) according to clinical phenotype	approximately 9 months

Secondary Outcome Measures

Name	Time	Method
Safety: Incidence of adverse events	approximately 9 months
Overall survival	approximately 9 months